Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies
August 07, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
MENLO PARK, Calif. and SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based...
Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer
July 20, 2018 10:30 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving...
Poseida Therapeutics Appoints John P. Schmid to Board of Directors
July 19, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today...
Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA
April 26, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, provided an...
Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
April 17, 2018 09:00 ET
|
Poseida Therapeutics, Inc.
Low dose cohort completed with rapid and clear signs of efficacy in all three patients, and no cytokine release syndrome Data presented at the American Association for Cancer Research (AACR) Annual...
Poseida Raises $30.5 Million in Series B Financing
April 03, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018
March 26, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
February 28, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies
February 14, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations
February 05, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...